A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Eli Lilly & CO stock. As of the latest transaction made, Citadel Advisors LLC holds 1,823,600 shares of LLY stock, worth $1.45 Billion. This represents 0.32% of its overall portfolio holdings.

Number of Shares
1,823,600
Previous 1,306,100 39.62%
Holding current value
$1.45 Billion
Previous $1.18 Billion 36.62%
% of portfolio
0.32%
Previous 0.24%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$772.14 - $960.02 $221 Million - $274 Million
-285,653 Reduced 57.04%
215,182 $191 Million
Q2 2024

Aug 14, 2024

BUY
$724.87 - $909.04 $17.2 Million - $21.6 Million
23,722 Added 4.97%
500,835 $453 Million
Q1 2024

May 15, 2024

SELL
$592.2 - $792.28 $473 Million - $633 Million
-798,919 Reduced 62.61%
477,113 $371 Million
Q4 2023

Feb 14, 2024

BUY
$525.19 - $619.13 $271 Million - $320 Million
516,239 Added 67.94%
1,276,032 $744 Million
Q3 2023

Nov 14, 2023

BUY
$434.7 - $599.3 $92.9 Million - $128 Million
213,671 Added 39.13%
759,793 $408 Million
Q2 2023

Aug 14, 2023

BUY
$350.74 - $468.98 $104 Million - $139 Million
296,101 Added 118.43%
546,122 $256 Million
Q1 2023

May 15, 2023

BUY
$310.63 - $364.82 $22.8 Million - $26.7 Million
73,307 Added 41.48%
250,021 $85.9 Million
Q4 2022

Feb 14, 2023

SELL
$321.55 - $374.67 $259 Million - $302 Million
-806,571 Reduced 82.03%
176,714 $64.6 Million
Q3 2022

Nov 14, 2022

SELL
$296.48 - $337.87 $53.9 Million - $61.4 Million
-181,800 Reduced 15.6%
983,285 $318 Million
Q2 2022

Aug 15, 2022

BUY
$278.73 - $327.27 $313 Million - $368 Million
1,123,361 Added 2692.36%
1,165,085 $378 Million
Q1 2022

May 16, 2022

SELL
$234.69 - $291.66 $21.7 Million - $27 Million
-92,520 Reduced 68.92%
41,724 $11.9 Million
Q4 2021

Feb 14, 2022

BUY
$224.85 - $279.04 $10.6 Million - $13.1 Million
47,019 Added 53.91%
134,244 $37.1 Million
Q3 2021

Nov 15, 2021

SELL
$221.6 - $272.71 $88.9 Million - $109 Million
-401,002 Reduced 82.13%
87,225 $20.2 Million
Q2 2021

Aug 16, 2021

BUY
$180.55 - $233.54 $68 Million - $87.9 Million
376,546 Added 337.16%
488,227 $112 Million
Q1 2021

May 17, 2021

SELL
$164.32 - $212.72 $331 Million - $428 Million
-2,013,741 Reduced 94.75%
111,681 $20.9 Million
Q4 2020

Feb 16, 2021

BUY
$130.46 - $172.63 $203 Million - $268 Million
1,554,906 Added 272.54%
2,125,422 $359 Million
Q3 2020

Nov 16, 2020

SELL
$146.22 - $169.13 $104 Million - $120 Million
-711,139 Reduced 55.49%
570,516 $84.4 Million
Q2 2020

Aug 14, 2020

BUY
$136.42 - $164.18 $173 Million - $209 Million
1,270,416 Added 11303.64%
1,281,655 $210 Million
Q1 2020

May 15, 2020

SELL
$119.05 - $147.35 $12 Million - $14.8 Million
-100,689 Reduced 89.96%
11,239 $1.56 Million
Q4 2019

Feb 14, 2020

SELL
$106.92 - $132.43 $23.9 Million - $29.6 Million
-223,548 Reduced 66.64%
111,928 $14.7 Million
Q3 2019

Nov 14, 2019

BUY
$106.79 - $116.16 $3.64 Million - $3.96 Million
34,070 Added 11.3%
335,476 $37.5 Million
Q2 2019

Aug 14, 2019

SELL
$110.79 - $129.32 $374 Million - $436 Million
-3,372,002 Reduced 91.79%
301,406 $33.4 Million
Q1 2019

May 15, 2019

BUY
$111.31 - $131.02 $368 Million - $433 Million
3,307,234 Added 903.19%
3,673,408 $0
Q4 2018

Feb 14, 2019

BUY
$105.9 - $118.64 $4.89 Million - $5.48 Million
46,164 Added 14.43%
366,174 $42.4 Million
Q3 2018

Nov 13, 2018

SELL
$85.86 - $107.31 $1.39 Million - $1.74 Million
-16,231 Reduced 4.83%
320,010 $0
Q2 2018

Aug 10, 2018

BUY
$75.7 - $86.88 $13.1 Million - $15 Million
172,940 Added 105.9%
336,241 $0
Q1 2018

May 11, 2018

BUY
$74.21 - $87.6 $9.88 Million - $11.7 Million
133,113 Added 440.95%
163,301 $12.6 Million
Q4 2017

Feb 09, 2018

SELL
$81.94 - $87.89 $7.13 Million - $7.65 Million
-87,004 Reduced 74.24%
30,188 $2.55 Million
Q3 2017

Nov 09, 2017

BUY
$77.07 - $85.54 $9.03 Million - $10 Million
117,192
117,192 $10 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.